10-Q: AptarGroup Reports Strong Q2 Earnings Growth Driven by Pharma and Closures Segments

AptarGroup, Inc. announced a significant increase in net income and earnings per share for the second quarter and first half of 2025, fueled by robust performance in its Pharma and Closures segments and effective cost management.

Summary

• Net sales for the second quarter of 2025 increased by 6% to $966.0 million, compared to $910.1 million in the same period of 2024.
• Core sales, excluding currency effects and acquisitions, grew by 3% in Q2 2025.
• Operating income rose by 14.6% to $144.4 million in Q2 2025, up from $126.0 million in Q2 2024.
• Net income attributable to AptarGroup, Inc. increased by 23.5% to $111.7 million in Q2 2025, compared to $90.5 million in Q2 2024.
• Diluted earnings per share (EPS) for Q2 2025 were $1.67, a 24.6% increase from $1.34 in Q2 2024.
• For the first six months of 2025, net sales increased by 2% to $1.85 billion, with core sales also up 2%.
• Six-month operating income increased by 8.3% to $257.8 million, and net income attributable to AptarGroup, Inc. grew by 9.8% to $190.5 million.
• Diluted EPS for the first six months of 2025 was $2.83, a 10.1% increase from $2.57 in the prior year.
• Adjusted EBITDA margin improved to 22.6% in Q2 2025 from 21.2% in Q2 2024, and to 21.7% for the first six months of 2025 from 20.4% in the prior year.
• Aptar Pharma segment's core sales increased by 3% in Q2, driven by strong demand in prescription drug, injectables, and active material science solutions, despite a 14% decline in consumer health care.
• Aptar Closures segment's core sales increased by 7% in Q2, primarily due to higher product sales in food and beverage markets.
• Aptar Beauty segment's core sales increased by 1% in Q2, mainly due to stronger tooling sales, though beauty market sales decreased by 4%.
• The effective tax rate for Q2 2025 was 20.0%, lower than 23.5% in Q2 2024, benefiting from an $8.3 million deferred tax benefit release.
• Net cash provided by operations for the first six months of 2025 was $208.7 million, a decrease from $235.9 million in the same period of 2024.
• Free cash flow for the first six months of 2025 was $91.7 million, slightly down from $92.0 million in the prior year.
• Total debt increased to $1.09 billion at June 30, 2025, from $1.03 billion at December 31, 2024, with the Net Debt to Net Capital ratio increasing to 25.2% from 24.4%.
• The company repurchased 1.0 million shares for $150.0 million during the first six months of 2025, with $312.7 million remaining under the $500 million authorization.

Sentiment

Score: 8

Explanation: The company reported strong financial results with significant increases in net sales, operating income, net income, and EPS. Margin expansion and effective cost management were evident. While there was a slight decrease in cash from operations and an increase in debt, the overall performance, positive segment contributions (especially Pharma and Closures), and a favorable tax benefit indicate a very positive outlook.

Positives

• Reported net sales increased by 6% in Q2 2025 and 2% for the first six months of 2025, demonstrating overall growth.
• Operating income saw significant increases of 14.6% in Q2 2025 and 8.3% for the first six months of 2025, reflecting improved operational efficiency.
• Net income attributable to AptarGroup, Inc. grew substantially by 23.5% in Q2 2025 and 9.8% for the first six months of 2025.
• Diluted EPS increased by 24.6% in Q2 2025 and 10.1% for the first six months of 2025, indicating enhanced profitability per share.
• Adjusted EBITDA margins improved across the board, reaching 22.6% in Q2 2025 and 21.7% for the first six months of 2025, driven by better product mix and cost management.
• Aptar Pharma segment showed strong core sales growth (3% in Q2, 3% in 6M) and improved Adjusted EBITDA margin (35.4% in Q2, 35.1% in 6M), particularly in prescription drug, injectables, and active material science solutions.
• Aptar Closures segment achieved robust core sales growth (7% in Q2, 3% in 6M) and improved Adjusted EBITDA margin (16.9% in Q2, 16.4% in 6M), primarily from food and beverage markets.
• Cost of sales as a percentage of net sales decreased due to an improved mix of higher-margin Pharma product sales and royalties, along with better operational performance and cost management initiatives.
• Selling, research & development and administrative expenses as a percentage of net sales decreased, reflecting successful cost optimization efforts.
• A deferred tax benefit of $8.3 million was recognized from the release of a valuation allowance, indicating profitable results in locations that previously operated with tax losses.
• The company maintains a strong financial position with significant borrowing capacity under its revolving credit facility (approximately $1.9 billion before exceeding maximum leverage ratio).
• Capital expenditures decreased by $26.9 million in the first six months of 2025 compared to the prior year, as larger projects were completed.

Negatives

• Net cash provided by operations decreased to $208.7 million in the first six months of 2025 from $235.9 million in the same period of 2024.
• Free cash flow slightly decreased to $91.7 million in the first six months of 2025 from $92.0 million in the prior year.
• Total debt increased to $1.09 billion at June 30, 2025, from $1.03 billion at December 31, 2024, leading to an increased Net Debt to Net Capital ratio of 25.2% from 24.4%.
• Interest expense increased by $0.8 million in Q2 2025 and $2.0 million in the first six months of 2025, primarily due to replacing lower-rate private placement debt with variable-rate term loan and revolving credit facility borrowings.
• Aptar Beauty segment experienced a 1% core sales decrease for the first six months of 2025, with beauty market sales declining by 7% due to softer European demand for prestige fragrance technologies and facial skin care products, and lower sales to the indie brand market.
• The consumer health care market within Aptar Pharma saw a significant core sales decline of 14% in Q2 and 12% for the first six months, mainly due to softer nasal decongestant, nasal saline, and cough and cold volumes.
• Personal care sales in Aptar Closures declined in Q2 due to lower tooling sales.
• Higher bad debt costs and compensation cost increases partially offset lower acquisition evaluation costs in SG&A for the first six months of 2025.
• Higher incentive compensation costs, including higher accrual rates for certain equity compensation programs, contributed to increased Corporate & Other costs for the first six months of 2025.

Risks

• Geopolitical conflicts worldwide, including the ongoing conflict in Ukraine with the Russian military, and their indirect impact on customer demand and supply chain disruptions.
• Cybersecurity threats against systems and/or service providers that could impact networks and reporting systems.
• Availability of raw materials and components, particularly from sole-sourced suppliers for some Pharma solutions, as well as the financial viability of these suppliers.
• Ability to protect and defend intellectual property rights, and litigation involving intellectual property rights.
• The outcome of any legal proceeding that has been or may be instituted against the company.
• Lower demand and asset utilization due to an economic recession either globally or in key markets.
• Economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions.
• Competition, including technological advances.
• Significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries.
• The execution of fixed cost reduction initiatives, including the optimization initiative.
• Ability to successfully implement facility expansions and new facility projects.
• Fluctuations in the cost of materials, components, transportation costs as a result of supply chain disruptions and labor shortages, and other input costs.
• Significant fluctuations in foreign currency exchange rates or the effective tax rate.
• The impact of tax reform legislation, changes in tax rates, and other tax-related events or transactions.
• Financial conditions of customers and suppliers.
• Consolidations within customer or supplier bases.
• Changes in customer and/or consumer spending levels.
• Loss of one or more key accounts.
• Ability to offset inflationary impacts with cost containment, productivity initiatives, and price increases.
• Changes in capital availability or cost, including rising interest rates.
• Volatility of global credit markets.
• Ability to identify potential new acquisitions and to successfully acquire and integrate such operations.
• Ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into existing product/service portfolio.
• Direct or indirect consequences of acts of war, terrorism, or social unrest.
• The impact of natural disasters and other weather-related occurrences.
• Fiscal and monetary policies and other regulations.
• Changes, difficulties, or failures in complying with government regulation, including FDA or similar foreign governmental authorities.
• Changing regulations or market conditions regarding environmental sustainability.
• Ability to retain key members of management and manage labor costs.
• Work stoppages due to labor disputes.
• Ability to meet future cash flow estimates to support goodwill impairment testing.
• The demand for existing and new products.
• The success of customers' products, particularly in the pharmaceutical industry.
• Ability to manage worldwide customer launches of complex technical products, particularly in developing markets.
• Difficulties in product development and uncertainties related to the timing or outcome of product development.
• Significant product liability claims.

Future Outlook

The company expects earnings per share for the third quarter of 2025 to be in the range of $1.53 to $1.61, excluding restructuring expenses, changes in the fair value of equity investments, and acquisition costs. This guidance is based on an estimated effective tax rate range of 20.5% to 22.5%. Total estimated cash outlays for capital expenditures net of government grant proceeds for 2025 are projected to be approximately $270 million to $290 million.

Management Comments

• Management believes the company is in a strong financial position to meet its business requirements in the foreseeable future.
• Management stated that if there were a prolonged decrease in customer demand adversely impacting cash flows from operations, the company would have the ability to restrict and significantly reduce capital expenditure levels and share repurchases, and reevaluate its acquisition strategy.

Industry Context

AptarGroup's performance reflects a diversified portfolio across critical markets. The strong growth in the Pharma segment, particularly in prescription drug and injectables, aligns with the robust demand in the healthcare sector for specialized delivery systems, including GLP-1 components. The Beauty segment's mixed results, with declines in prestige fragrance and indie brand skincare, suggest sensitivity to evolving consumer trends and potential market saturation in certain luxury sub-segments, alongside tariff-related uncertainties. Conversely, the strength in personal care (hair/body/skin care) indicates resilience in broader consumer staples. The consistent growth in the Closures segment, driven by food and beverage, highlights the stable demand for essential consumer goods packaging. The company's ability to leverage its global presence and product diversification helps mitigate weaknesses in specific sub-markets.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry standard comparisons.

Legal Proceedings

• Subject to lawsuits and claims, both actual and potential, including those involving intellectual property and commercial disputes.
• Involved in legal proceedings related to alleged infringement of intellectual property rights, alleged customer breach of confidentiality obligations, and alleged customer misuse of proprietary information.
• Received claims for custom duties assessments totaling approximately $9 million to $10 million in principal, and $23 million to $24 million for interest and penalties, with no liability recorded as of June 30, 2025, due to uncertainty in settlement probability and appeal timing.

Related Party Transactions

• Purchases of $5.6 million from BTY (an equity method investment) for the six months ended June 30, 2025.
• Approximately $2.2 million was due to BTY and included in accounts payable, accrued and other liabilities as of June 30, 2025.

Stakeholder Impact

• Shareholders: Benefited from increased net income, EPS, and dividends per share. The ongoing share repurchase program and expected non-cash gain from the BTY acquisition in Q3 2025 are positive.
• Employees: Domestic noncontributory retirement plans were closed to new employees after January 1, 2021, with new employees eligible for additional 401(k) contributions, while existing employees continue to accrue pension benefits. Stock-based compensation programs are in place.
• Customers: Experienced strong demand for products in the prescription drug, injectables, active material science, food, and beverage markets. However, there was softer demand in consumer health care, prestige fragrance, and indie brand skincare.
• Suppliers: The company facilitates a supply chain finance program in Europe and the U.S. to enable early payments for eligible suppliers. Risks related to raw material/component availability and supplier financial viability are noted.
• Creditors: Total debt increased, and the Net Debt to Net Capital ratio rose. However, the company remains well within its financial covenants (Consolidated Leverage Ratio of 1.19 to 1.00 vs. maximum 3.50 to 1.00; Consolidated Interest Coverage Ratio of 17.40 to 1.00 vs. minimum 3.00 to 1.00).

Next Steps

• Complete the initial purchase accounting for the acquisition of an additional 31% of BTY's equity interests, to be included in the third quarter Form 10-Q filing.
• Consolidate the BTY business into the Aptar Beauty segment during the third quarter Form 10-Q filing.
• Evaluate the impact of ASU 2023-09 (Improvements to Income Tax Disclosures) for adoption in the fourth quarter of 2025.
• Evaluate the impact of ASU 2024-03 (Disaggregation of Income Statement Expenses) for adoption in the fourth quarter of 2026.
• Pay a quarterly cash dividend of $0.45 per share on August 14, 2025.
• Continue share repurchases under the existing $500 million authorization, with $312.7 million remaining as of June 30, 2025.

Key Dates

Recommendation

AptarGroup delivered strong financial results with significant growth in net sales, operating income, and EPS, driven by robust performance in its Pharma and Closures segments and effective cost management. The improved Adjusted EBITDA margins and a favorable tax benefit are notable positives. However, the slight decrease in net cash provided by operations and an increase in total debt, along with some softness in specific sub-segments of the Beauty and Pharma markets, suggest a 'Hold' recommendation. While the company is performing well and has a positive outlook, a seasoned investor would monitor these areas for sustained improvement and evaluate the impact of rising interest rates on debt costs before considering a 'Buy' or 'Strong Buy'.

Keywords

Dispensing Systems, Drug Delivery, Sealing Solutions, Packaging, Pharmaceutical, Beauty, Personal Care, Food & Beverage, Healthcare, Manufacturing, Specialty Packaging, Q2 Earnings, SEC Filing, 10-Q, Financial Results